Biostem Technologies 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
BioStem Technologies announced strong sequential revenue growth of 29% to $7.9 million for Q2 2026, raised full-year guidance, and successfully uplisted to the Nasdaq Capital Market.